Zymeworks (ZA8) Price & Analysis

0 Followers

ZA8 Stock Chart & Stats

€22.82

-€0.09(-0.45%)

At close: Jul 24 4:00 PM EDT

€22.82

-€0.09(-0.45%)

Day’s Range― - ―

52-Week Range€13.70 - €26.33

Previous CloseN/A

Volume0.00

Average Volume (3M)1.00

Market Cap

€1.65B

Enterprise Value€1.91B

Total Cash (Recent Filing)€270.70M

Total Debt (Recent Filing)€268.64M

Price to Earnings (P/E)―

Beta0.27

Next Earnings

Nov 10, 2026

EPS Estimate

2.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.02

Shares Outstanding70,959,240

10 Day Avg. Volume0

30 Day Avg. Volume1

Financial Highlights & Ratios

PEG Ratio0.73

Price to Book (P/B)7.39

Price to Sales (P/S)18.72

P/FCF Ratio-57.45

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€36.43

Price Target Upside59.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)0.92

Revenue Forecast (FY)€263.84M

Bulls Say, Bears Say

Bulls Say

Revenue DiversificationThe completed Theravance transaction broadens Zymeworks beyond clinical-stage development by adding YUPELRI profit-sharing and royalty streams. This diversification can create recurring funding for R&D and reduce dependence on sporadic licensing milestones over the next several quarters.

Cash PositionA $322.5 million cash position provides meaningful financial capacity for clinical development, partnerships and other strategic initiatives. That liquidity can help sustain investment in the pipeline and support operations while the company transitions toward more diversified revenue sources.

Proprietary Platform And PipelineZymeworks’ proprietary antibody engineering platforms provide a technology base for developing multispecific therapeutics across oncology and other severe diseases. A platform approach can support multiple programs and partnerships, creating opportunities for milestone, licensing and royalty income.

Bears Say

Persistent Cash BurnContinued negative operating and free cash flow means the business is not yet self-funding and must rely on its cash balance, financing or partner payments. Persistent cash consumption can constrain R&D flexibility and increase dependence on successful pipeline or licensing milestones.

Revenue And Profitability WeaknessA sharp TTM revenue decline combined with recurring losses weakens the company’s earnings base and makes operating performance dependent on uneven deals or milestones. Sustained losses can limit internal reinvestment and increase the importance of successful commercialization and partnerships.

Secured Debt BurdenThe new secured financing adds fixed interest obligations and places first-priority liens on substantially all assets of guaranteed entities. Its covenants and change-of-control protections may limit financial flexibility, while repayment obligations increase execution risk during the integration period.

Zymeworks News

Zymeworks price target raised to $34 from $32 at Truist

Truist raised the firm’s price target on Zymeworks (ZYME) to $34 from $32 and keeps a Buy rating...

4d ago

ZYME

Zymeworks reinstated with a Buy at TD Cowen

TD Cowen analyst Yaron Werber reinstated coverage of Zymeworks (ZYME) with a Buy rating and $34 price target...

12d ago

ZYME

Zymeworks price target raised to $39 from $38 at Citi

Citi raised the firm’s price target on Zymeworks (ZYME) to $39 from $38 and keeps a Buy rating...

12d ago

ZYME

LifeSci flags Yupelri as a key growth driver after Zymeworks’ Theravance deal

LifeSci Capital notes Zymeworks (ZYME) announced the completion of the Theravance Biopharma (TBPH) acquisition. Yupelri is expected to...

13d ago

ZYME

Midday Fly By: Nvidia boosts buyback, Boeing discovers 737 Max glitch

The major averages were broadly lower to start the week, with oil prices surging over 3% after President...

13d ago

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera...

13d ago

ZYME

Zymeworks announces financial impact of Theravance Biopharma acquisition

The acquisition is expected to provide Zymeworks (ZYME) with meaningful and immediate incremental revenue and operating cash flow...

13d ago

ZYME

Zymeworks initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Zymeworks (ZYME) with an Outperform rating. Published first on TheFly – the ultimate...

24d ago

ZYME

Charles Zhu Reiterates Buy on Zymeworks, Keeps $34 Price Target After TBPH Acquisition Boosts Growth and Cash Flow Outlook

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Zymeworks. The associated price target remains...

13d ago

ZYME

Zymeworks Closes Theravance Acquisition and CVR Financing

An update from Zymeworks ( ($ZYME) ) is now available. On September 22, 2026, Zymeworks entered into a...

18d ago

ZYME

Zymeworks price target raised to $33 from $31 at JPMorgan

JPMorgan raised the firm’s price target on Zymeworks (ZYME) to $33 from $31 and keeps an Overweight rating...

1M ago

ZYME

Zymeworks price target raised to $38 from $37 at Citi

Citi raised the firm’s price target on Zymeworks (ZYME) to $38 from $37 and keeps a Buy rating...

2M ago

ZYME

Zymeworks Gains $250 Million Milestone as Jazz Wins FDA Nod for HER2 Cancer Regimens

The latest update is out from Zymeworks ( ($ZYME) ). Zymeworks Inc. reported that its partner Jazz Pharmaceuticals...

2M ago

ZYME

Zymeworks Gains Second FDA Nod for Zanidatamab, Unlocking Major Milestones

Zymeworks ( ($ZYME) ) just unveiled an update. Zymeworks’ partner Jazz Pharmaceuticals has secured U.S. FDA approval for...

2M ago

ZYME

ZA8 FAQ

What was Zymeworks Inc’s price range in the past 12 months?

Zymeworks Inc lowest stock price was €13.70 and its highest was €26.33 in the past 12 months.

What is Zymeworks Inc’s market cap?

Zymeworks Inc’s market cap is €1.65B.

When is Zymeworks Inc’s upcoming earnings report date?

Zymeworks Inc’s upcoming earnings report date is Nov 10, 2026 which is in 30 days.

How were Zymeworks Inc’s earnings last quarter?

Zymeworks Inc released its earnings results on Aug 06, 2026. The company reported -€0.552 earnings per share for the quarter, missing the consensus estimate of -€0.512 by -€0.04.

Is Zymeworks Inc overvalued?

According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zymeworks Inc pay dividends?

Zymeworks Inc does not currently pay dividends.

What is Zymeworks Inc’s EPS estimate?

Zymeworks Inc’s EPS estimate is 2.04.

How many shares outstanding does Zymeworks Inc have?

Zymeworks Inc has 70,959,240 shares outstanding.

What happened to Zymeworks Inc’s price movement after its last earnings report?

Zymeworks Inc reported an EPS of -€0.552 in its last earnings report, missing expectations of -€0.512. Following the earnings report the stock price went down -1.869%.

Which hedge fund is a major shareholder of Zymeworks Inc?

Currently, no hedge funds are holding shares in DE:ZA8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zymeworks Stock Smart Score

Outperform

Fundamentals

Return on Equity

-72.07%

Trailing 12-Months

Asset Growth

-2.80%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Zymeworks Inc

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Zymeworks (ZA8) Earnings & Revenues

Historic Earnings Reports

ZA8 Stock 12 Month Forecast

Average Price Target

€36.43

▲(59.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"€13","50":"€50","22.25":"€22.3","31.5":"€31.5","40.75":"€40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49.0720912,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€49.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.43231013333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€36.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.44325472,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€29.44</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,22.25,31.5,40.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.69,24.71939163076923,26.748783261538463,28.778174892307696,30.807566523076925,32.836958153846155,34.86634978461539,36.89574141538462,38.925133046153846,40.954524676923086,42.98391630769231,45.01330793846154,47.04269956923078,{"y":49.0720912,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.69,23.74710077948718,24.804201558974363,25.86130233846154,26.91840311794872,27.9755038974359,29.03260467692308,30.08970545641026,31.14680623589744,32.203907015384615,33.2610077948718,34.31810857435898,35.37520935384616,{"y":36.43231013333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.69,23.209481132307694,23.728962264615387,24.24844339692308,24.76792452923077,25.28740566153846,25.806886793846154,26.326367926153846,26.84584905846154,27.365330190769228,27.884811323076924,28.404292455384613,28.923773587692306,{"y":29.44325472,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.25,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.265,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.42,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.69,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >